InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
InterCure Ltd. Receives Nasdaq Non-Compliance Notice, Granted Until August 24, 2026 To Regain Compliance
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million
InterCure Posts Preliminary NIS 265M Revenue For 2025, An 11% YoY Rise, With 2H Revenue Nearly 20% Higher Than Prior Year
Trump's Marijuana Reclassification Looks Set To Send This Cannabis ETF Soaring: Big Surge In Momentum
InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
InterCure Enters Into Definitive Share Purchase Agreement And Collaboration Agreement With Cannasoul To Advance Cannabis Science And Pharmaceutical Innovation
Intercure H1 EPS $0.01 Up From $0.00 YoY, Sales $36.292M Miss $66.530M Estimate
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
Middle Eastern Penny Stocks With Market Caps Over US$1M
InterCure Enters Premium US Cannabis Market With ISHI Deal
InterCure to Acquire Cannabis Brand Botanico in Two-Phase Deal
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
InterCure Acquires Botanico (aka ISHI) In All-Stock Deal Worth 4.92M Ordinary Shares To Expand Cannabis Portfolio
August 2025's Middle Eastern Penny Stocks: Discovering Hidden Opportunities
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025
InterCure Annual Revenue For The Year Ended December 31, 2024 Was NIS239 Million
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
